Detail of "130465-39-3"

Reference

Killing human lymphoma and leukemia cancer cells and TCR-activated normal human cells with dopamine D1 receptor agonists

All Rights Reserved. Killing human lymphoma and leukemia cancer cells and TCR-activated normal human cells with dopamine D1 receptor agonists. Levite, Mia (Mineuet Therapeutics Ltd.; Geraghty, Erin, Israel). PCT Int. Appl. WO 2007019266 A2 15 Feb 2007, 71pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). (World Intellectual Property Organization). CODEN: PIXXD2. APPLICATION: WO 2006-US30360 3 Aug 2006. PRIORITY: US 2005-704728P 3 Aug 2005. DOCUMENT TYPE: Patent CA Section: 1 (Pharmacology) The dopamine D1/D5 receptor is highly over-expressed in various types of human and animal leukemia, lymphoma and activated T-cells. The dopamine D1 receptor is also expressed in dramatically elevated or even moderate levels in other types of cancer cells. Selective dopamine D1 receptor agonists, e.g. fenoldopam mesylate, rapidly, potently and selectively kill such human and animal T-cells expressing the dopamine D1 receptor. Thus, selective dopamine D1/D5 receptor agonists may be used to treat lymphoma, leukemia and other cancers of the immune system, and T-cell mediated autoimmune diseases and other diseases caused by over-activated inflammatory T-cells (such as chronic inflammation), or graft vs. host diseases (GVHD) or graft rejection, or by any other cell types expressing the dopamine D1 receptor, by killing the disease-causing cells. The selective dopamine D1/D5 receptor agonists can be used for these purposes either in vivo or in vitro, e.g. 130465-39-3 and 145307-34-2 are just another two chemicals used in this study. to purge a given cell population from undesired leukemia, lymphoma or activated T-cells prior to further use. .